These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38813782)

  • 1. A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance.
    Teymouri F; Dasanu CA
    J Oncol Pharm Pract; 2024 May; ():10781552241258175. PubMed ID: 38813782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
    Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
    Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-Induced Palmar-Plantar Erythrodysesthesia.
    Wahab A; Khakwani M; Ehsan H; Bellam N
    Cureus; 2020 Nov; 12(11):e11507. PubMed ID: 33214972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palmar-plantar erythrodysesthesia secondary to docetaxel chemotherapy: a case report.
    Benghiat H; Al-Niaimi A
    J Med Case Rep; 2011 Feb; 5():80. PubMed ID: 21352522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer drug induced palmar plantar erythrodysesthesia.
    Palaniappan M; Srinivasamurthy S; Dubashi B; Chandrasekaran A
    J Clin Diagn Res; 2014 Oct; 8(10):HC01-3. PubMed ID: 25478366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE).
    Law A; Dyson S; Anthony D
    J Adv Nurs; 2015 Aug; 71(8):1825-32. PubMed ID: 25702709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma.
    Ota H; Munechika M; Tobino K; Uchida K; Muarakami Y
    Cureus; 2024 Apr; 16(4):e58253. PubMed ID: 38745801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palmar-plantar Erythrodysesthesia with Genital Involvement Secondary to Capecitabine Chemoradiotherapy: A Case Report.
    Hu HP; Corkum MT; Perera F
    Cureus; 2018 Dec; 10(12):e3704. PubMed ID: 30788193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy.
    Fontenot AL; Furr WJ; Husan A; Khan MW
    Cureus; 2021 Nov; 13(11):e20060. PubMed ID: 34993032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
    Farr KP; Safwat A
    Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
    Meadows KL; Rushing C; Honeycutt W; Latta K; Howard L; Arrowood CA; Niedzwiecki D; Hurwitz HI
    Support Care Cancer; 2015 May; 23(5):1311-9. PubMed ID: 25341548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 14. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review.
    Salloum A; Habre M; Chebl JA; Chebl KA; Atallah C; Medawar G; Kourie HR
    Immunotherapy; 2022 Apr; 14(6):489-503. PubMed ID: 35232283
    [No Abstract]   [Full Text] [Related]  

  • 15. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD; How C; Harrold K
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 17. Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma.
    Habibi S; Soliman A; Dasanu CA
    J Oncol Pharm Pract; 2023 Jul; 29(5):1255-1258. PubMed ID: 36597613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
    Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
    Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
    Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.